Discovery Life Sciences Acquires AllCells
CREATES PREMIER GLOBAL PROVIDER OF CRITICAL STARTING MATERIALS AND ANALYTIC SERVICES TO ACCELERATE CELL AND GENE THERAPY APPLICATIONS
HUNTSVILLE, Ala. and ALAMEDA, Calif., July 12, 2022 /PRNewswire/ — Discovery Life Sciences™ (Discovery), the biospecimen and biomarker specialists™, today announced its acquisition of AllCells®, a leading provider of clinical-grade (GMP-compliant) and Research Use Only (RUO) primary cell products. With more than 30 years of collective cell and gene therapy (CGT) experience, AllCells and Discovery will focus on providing revolutionary products and services with greater speed and reliability to satisfy the entire CGT continuum ─ from basic discovery through commercialization.
Founded in 1998 by Jay Tong, M.D., AllCells is a leading global provider in procuring and customizing primary cell products to support a diversity of CGT applications. Combining AllCells’ proven industry expertise with Discovery’s biospecimen and biomarker specialization establishes the premier provider for critical starting materials and analytic services to accelerate CGT applications.
“We are very excited to welcome the AllCells team to the Discovery family,” said Discovery CEO Glenn Bilawsky. “Bringing these two great companies together creates a scalable, end-to-end solution that gives our clients unprecedented access to reliable human cellular starting materials with integrated multi-omic analytic services to support cell and gene therapies.”
Discovery will combine its existing CGT products and services with AllCells to create a new business unit called AllCells, a Discovery Life Sciences Company. Effective immediately, AllCells CEO and President Danny Zheng will lead the combined entity.
The combination of Discovery’s growing CGT business with AllCells also creates one of the industry’s largest dedicated client donor pools. The FDA-registered donor collection facilities and GMP-compliant cleanrooms are located adjacent to characterization labs. This proximity strategically enables immediate processing and cryopreservation for unparalleled quality ― providing customers faster and more cost-effective access to a larger, engaged donor pool with characterization for client-specific programs.
Zheng said, “We have built our organization to be an extension of our client’s supply chain. By offering donor program consulting, high-quality apheresis collections, customization services, and GMP-compliant starting materials, our dedicated team will continue to provide a high-touch, client-focused approach to ensure our clients’ needs are met with superior products and services to fit any timeline and on any scale. Our strategy parallels and reinforces Discovery’s ‘Science at your Service’ approach, and our unified offerings will further accelerate our clients’ strategic and vital cell and gene therapy programs.”
“The promise of CGT to impact patient health is unquestionable, but improvements in manufacturing and reproducibility are needed to expand addressable patient populations and enhance treatment paradigms,” said Discovery’s Chief Technical Officer, CGT Dominic Clarke. “Our solution delivers access to the entire continuum from RUO to GMP starting materials, informed by integrated, comprehensive characterization at scale, to support these rapidly expanding needs of the industry.”
About Discovery Life Sciences
Discovery Life Sciences, the Biospecimen and Biomarker Specialists™, is a leading provider of highly characterized human cellular starting materials integrated with expert multi-omic analytical services to advance cell and gene therapy research, development, and manufacturing. We offer one of the largest recallable donor pools, Research Use Only (RUO) and clinical-grade (GMP) fresh and cryopreserved human cellular materials to support cell and gene therapy programs at any scale from start to finish.
Driven by leading scientific expertise and innovative use of current technologies, the Discovery team engages and consults with customers to rapidly overcome obstacles and obtain results to make critical research, development, and manufacturing decisions at market-leading speed. We are Science at your Service™! For more information, visit dls.com/cell-and-gene-therapy-products.
For over two decades, AllCells has been a leading provider of high-quality human primary blood and marrow-based cells. Through experience and scientific expertise, AllCells maintains the best-in-class products and services with optimized protocols that ensure research and clinical-grade products are delivered on time to pharmaceutical, biotechnology, medical device, healthcare, and academic institutions around the world.
By consistently delivering high-viability, high-purity subtypes and guaranteeing an accurate cell count, AllCells has earned a reputation for high-quality cells with the ability to customize our product to meet even the most unique requirements. AllCells – Quality Cells for Quality Science™.
Logo – https://mma.prnewswire.com/media/1022478/Discovery_LS_Logo.jpg
Logo – https://mma.prnewswire.com/media/1856962/AllCells_logo.jpg
The content is by PR NewsWire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.